纤维化性间质性肺疾病患者的管理
本文总结纤维化性间质性肺疾病治疗药物的合理使用与药理学,重点介绍抗纤维化药物尼达尼布和吡非尼酮。FDA于2014年批准两药用于特发性肺纤维化,后续尼达尼布又获批用于系统性硬化相关间质性肺病及进展表型间质性肺病。药师在多学科团队中的作用日益重要。
要点
- 尼达尼布和吡非尼酮是FDA批准用于特发性肺纤维化的抗纤维化药物。
- 尼达尼布还获批用于系统性硬化相关间质性肺病和进展表型间质性肺病。
- N-乙酰半胱氨酸、抗凝和肺血管扩张剂缺乏疗效或造成伤害。
核心结论
- 随着纤维化性间质性肺疾病有效药物治疗的出现,药师在多学科团队管理中角色日益重要。
研究设计与样本
- 本文为综述,总结纤维化性间质性肺疾病治疗药物的合理使用与药理学。
主要发现
- 特发性肺纤维化是最常见的纤维化性间质性肺疾病。
- FDA于2014年批准尼达尼布和吡非尼酮用于特发性肺纤维化。
- 后续FDA批准尼达尼布用于系统性硬化相关间质性肺病和进展表型间质性肺病。
- N-乙酰半胱氨酸、抗凝和肺血管扩张剂缺乏疗效或造成伤害。
关键数值与推荐
- 所有患者应提供支持性护理和肺康复。
- 免疫调节剂和/或免疫抑制剂的作用因基础疾病状态而异。
临床怎么用
- 药师应参与纤维化性间质性肺疾病患者的多学科管理。
- 关注抗纤维化药物的合理使用与药理学。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This article summarizes the appropriate use and pharmacology of treatments for fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib and pirfenidone. SUMMARY: The interstitial lung diseases are a heterogenous group of parenchymal lung disorders with a common feature-infiltration of the interstitial space with derangement of the normal capillary-alveolar anatomy. Diseases characterized by fibrosis of the interstitial space are referred to as the fibrosing interstitial lung diseases and often show progression over time: idiopathic pulmonary fibrosis is the most common fibrotic interstitial lung disease. Historically, therapies for fibrosing lung diseases have been limited in number, questionable in efficacy, and associated with potential harms. Food and Drug Administration (FDA) approval of the antifibrotic agents nintedanib and pirfenidone for idiopathic pulmonary fibrosis in 2014 heralded an era of reorganization of therapy for the fibrotic interstitial lung diseases. Subsequent investigations have led to FDA approval of nintedanib for systemic sclerosis-associated interstitial lung disease and interstitial lung diseases with a progressive phenotype. Although supportive care and pulmonary rehabilitation should be provided to all patients, the role(s) of immunomodulators and/or immune suppressing agents vary by the underlying disease state. Several agents previously used to treat fibrotic lung diseases (N-acetylcysteine, anticoagulation, and pulmonary vasodilators) lack efficacy or cause harm. CONCLUSION: With the introduction of effective pharmacotherapy for fibrosing interstitial lung disease, pharmacists have an increasingly important role in the interdisciplinary team managing these patients.
引用
- Morrow LE, Hilleman D, Malesker MA, et al. Management of patients with fibrosing interstitial lung diseases. Am J Health Syst Pharm. 2022. PMID: 34608488. doi:10.1093/ajhp/zxab375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。